Pathology of RUNX1-ETO/MPL myeloid leukemia. (A) Quantification of peripheral blood WBCs from recipient mice expressing MID-Mpl, MIG-R1E9a/MID-MIG, MIG-R1E9a/MID-Mpl, and MIG-R1E/MID-Mpl. Individual values (triangle) and mean (line) are represented. (B) Representative immature cells detected in peripheral blood of MIG-R1E/MID-Mpl (left) and MIG-R1E-MID (right) leukemic mice; original magnification 100×. (C) Representative flow cytometric analysis of GFP(+)/hCD4(+) gated peripheral blood from MIG-R1E9a/MID (top) and MIG-R1E9a/MID-Mpl (bottom) leukemic mice, for lineage (CD41, CD3 B220, Mac1, Gr1, and Ter119) and leukemic cell marker (c-kit). (D) Spleen cross sections showing the architecture of wild-type (wt; 16 weeks old) spleen, and MIG-R1E9a/MID-Mpl (14 weeks old), and MIG-R1E/MID (26 weeks old) spleens from leukemic mice (original magnification ×50). (E) Time course analysis of erythroid progenitors in peripheral blood of recipients transduced with MID-Mpl (n = 8). The percentage of donor cells hCD4(+) cells expressing Mpl (left) and Ter119(+) (right) cells.